Lv2
110 积分 2025-10-15 加入
Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study
5天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy
1个月前
已完结
中国成人IgA肾病及IgA血管炎肾炎临床实践指南（2025）
1个月前
已完结
IgA Nephropathy
1个月前
已完结
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
1个月前
已完结
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
1个月前
已完结
IgA Nephropathy
1个月前
已完结
Association of Inflammatory Bowel Disease with Incident IgA Nephropathy
1个月前
已完结
皖公网安备34019202002308
